Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.68 |
| ▸ | HTR2A | P28223 | 5/20 | 0.68 |
| ▸ | HTR1A | P08908 | 5/20 | 0.68 |
| ▸ | DRD2 | P14416 | 1/20 | 0.68 |
| ▸ | HTR7 | P34969 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5456512 | 0.99 | HTR6 (0.67) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL14373103 | 0.89 | HTR6 (0.64) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL5176730 | 0.88 | HTR6 (0.63) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL19327038 | 0.86 | HTR6 (0.72) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL14400458 | 0.85 | HTR6 (0.82) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL5159659 | 0.85 | HTR6 (0.68) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL5161801 | 0.84 | HTR6 (0.67) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL14373100 | 0.84 | HTR1A (0.69) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL19327045 | 0.84 | HTR2A (0.69) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL15503471 | 0.83 | HTR6 (0.80) | HTR6HTR2AHTR1ADRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249603-A1 | 3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249603-A1 | 3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249603-A1 | 3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249603-A1 | 3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | HTR6, HTR3B, HTR1A | HTR6 1/4885HTR2A 6/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.